Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

NCT04655898 | Completed Phase 1 FDA Drug

• 2 other identifiers: CC-90001-CP-007U1111-1261-4819
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

This is a clinical pharmacology study to characterize the biotransformation and excretion of \[14C\]CC-90001 and to evaluate the safety and tolerability of \[14C\]CC-90001 following a single oral dose of \[14C\]CC-90001 in healthy male subjects. Approximately 8 subjects will be enrolled into the study with a goal of 6 subjects being eligible for analysis.

Conditions

Healthy Volunteer

Keywords

Mass balance; Males; Healthy volunteers; CC-90001; [14C]CC-90001

Outcome Measures

Primary Outcomes (9)

• Pharmacokinetics - Total [14C]-RA

  Total \[14C\]-Radioactivity (RA) in whole blood, plasma, urine, and feces) will be measured via Liquid scintillation counting (LSC)

  Up to approximately 216 hours post dose

• Pharmacokinetics - Cumulative excretion of total [14C]-RA

  The total recovery of radioactivity will be computed as the sum of the cumulative excretion (as % dose) in urine and feces

  Up to approximately 13 days

• Pharmacokinetics - Total [14C]-RA whole blood-to-plasma ratios

  Total \[14C\]-RA in whole blood and plasma will be converted to ngEq/mL concentration of \[14C\]CC-90001 based on specific activity of the dose. Equivalent concentration-time profiles will be determined.

  Up to approximately 216 hours post

• Pharmacokinetics - metabolite profiling in plasma

  The RA will be determined for CC-90001 and any identified metabolites in plasma. Metabolite profiling may use pooled time points.

  Up to approximately 216 hours post

• Pharmacokinetics - metabolite profiling in urine and feces

  Percentage of the administered dose, and the RA, will be determined for CC-90001 and any identified metabolites in urine and feces. Metabolite profiling may use pooled collection intervals.

  Up to approximately 13 days

• Pharmacokinetics - Cmax

  Observed maximum concentration of \[14C\]CC-90001 and for metabolites with sufficient measurable concentration

  Up to approximately 216 hours post

• Pharmacokinetics - AUC

  Area under the concentration-time curve of \[14C\]CC-90001 and for metabolites with sufficient measureable concentration

  Up to approximately 216 hours post

• Pharmacokinetics - Tmax

  Time to Cmax of \[14C\]CC-90001 and for metabolites with sufficient measureable concentration

  Up to approximately 216 hours post

• Pharmacokinetics - t1/2

  Terminal elimination half-life of \[14C\]CC-90001 and for metabolites with sufficient measureable concentration

  Up to approximately 216 hours post

Secondary Outcomes (1)

• Number of treatment-emergent adverse event related to CC-90001

  From enrollment until at least 28 days after completion of study treatment

Study Arms (1)

Administration of [14C]CC-90001

EXPERIMENTAL

A single oral dose of \[14C\]CC-90001, containing approximately 100 μCi of radioactivity, will be administered on Day1 under fasted conditions.

Drug: [14C]CC-90001

Interventions

[14C]CC-90001 DRUG

Oral

Administration of [14C]CC-90001

Eligibility Criteria

• Age: 18 Years - 55 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects must satisfy the following criteria to be enrolled in the study:
• Subject is ≥18 and ≤55 years of age, from any race, at the time of signing the informed consent form (ICF).
• Subject is a male.
• Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
• Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
• Subject is in good health, as determined by the Investigator based on a physical examinations and laboratory testing at screening or at check-in.
• Must practice true abstinence or agree to use a barrier method of birth control (condoms not made out of natural \[animal\] membrane \[latex condoms are recommended\]) during sexual contact with a pregnant female or female of childbearing potential (FCBP) on the day of taking the single dose of study drug and for at least 90 days after taking the single dose of study drug. This also applies to those subjects who have had a successful vasectomy.
• Subject has a body mass index (BMI) ≥ 18 and ≤ 33kg/m2 at screening.
• Subject is afebrile, with supine systolic blood pressure (BP) ≥ 90 and ≤ 160mmHg, supine diastolic BP ≥ 50 and ≤ 100 mmHg, and pulse rate ≥ 40 and ≤ 90bpm at screening and check-in.
• Subject has screening laboratory test results within the reference range or, if outside the reference range, documented to be not clinically significant by the Investigator.
• Subject has a normal or clinically acceptable 12-lead electrocardiogram (ECG), with a QT interval corrected using Fredericia formula (QTcF) value ≤ 450 msec, at screening and check-in

You may not qualify if:

• Subject has any significant medical condition, laboratory observation, or psychiatric illness that would prevent the subject from participating in the study.
• Subject has any condition including a laboratory test result which places the subject at unacceptable risk if he were to participate in the study.
• Subject has any condition that confounds the ability to interpret data from the study.
• Subject was exposed to an investigational drug (new chemical entity) within 30days prior to dosing, or 5half-lives of that investigational drug, if known (whichever is longer).
• Subject has used any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 14 days or 5 half-lives of that medication, whichever is longer, prior to dosing.
• Subject has used any non-prescribed systemic or topical medication (including vitamin/mineral supplements and herbal medicines) within 7days prior to dosing.
• Subject has used CYP3A inducers and/or inhibitors (including St. John's Wort) within 30days prior to dosing. The Indiana University "Cytochrome P450 Drug Interaction Table" should be utilized to determine inducers and/or inhibitors of CYP3A (http://medicine.iupui.edu/clinpharm/ddis/table.aspx). Please consult the medical monitor for any uncertainties with regard to potential CYP3A modulators.
• Subject has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, eg, bariatric procedure or Gilbert's syndrome.
• Has donated blood or plasma within 2weeks before dose administration to a blood bank or blood donation center.
• Subject has a history of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual \[DSM\]) within 2 years prior to dosing, or positive drug test reflecting consumption of drugs of abuse.
• Subject has a history of alcohol abuse (as defined by the current version of the DSM) within 2 years prior to dosing, or positive alcohol test.
• Positive SARS-CoV-2 (severe acute respiratory syndrome coronavirus) test or signs/symptoms of COVID-19 (Coronavirus Disease 2019) infection.
• Subject is known to have serum hepatitis or be a carrier of Hepatitis B virus (HBV) or Hepatitis C virus (HCV); or express hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV Ab), or have a positive result to the test for human immunodeficiency virus (HIV) antibodies at screening.
• Smokers or users of other tobacco products (self-reported).
• Subject has received immunization with a live or live attenuated vaccine within 1 months prior to dosing or is planning to receive immunization with a live or live attenuated vaccine for 1months following dosing.

Sponsors & Collaborators

• Celgene: lead

Study Sites (1)

Covance Clinical Research Unit Inc

Madison, Wisconsin, 53704, United States

Location

Study Officials

• Leon Carayannopoulos, MD

  Bristol-Myers Squibb

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 3, 2020
• First Posted: December 7, 2020
• Study Start: December 16, 2020
• Primary Completion: March 11, 2021
• Study Completion: March 11, 2021
• Last Updated: June 25, 2021

Record last verified: 2021-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
• Time Frame: See Plan Description
• Access Criteria: See Plan Description

Locations

US (1)